Sarepta shares under pressure, analysts flag risks after second Elevidys-linked death
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI
June 17, 2025 4:02 PM EDTEvercore ISI analyst Gavin Clark-Gartner lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $28.00 (from $50.00) while maintaining a In Line rating.
The analyst comments "Following the second recent Elevidys-related death due to liver failure, were reiterating our In-Line rating and lowering our PT to $28/sh. See our previous downgrade note for more details on the broader setup. Some thoughts on the path forward: Tough to... More
Goldman Sachs Downgrades Sarepta Therapeutics (SRPT) to Neutral
June 17, 2025 7:14 AM EDTGoldman Sachs analyst Salveen Richter downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Buy to Neutral with a price target of $29.00.
The analyst comments "We downgrade SRPT to Neutral from Buy as we see an uncertain outlook amidst safety concerns, following the second reported death of a non-ambulatory Elevidys-treated Duchenne muscular dystrophy patient due to acute liver failure (ALF). SRPT plans to convene a Duchenne and liver health expert panel to consider enhanced immunosuppression, as the company believes that adding... More
Morgan Stanley Downgrades Sarepta Therapeutics (SRPT) to Equalweight
June 16, 2025 2:47 PM EDTMorgan Stanley analyst Matthew Harrison downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Equalweight with a price target of $40.00 (from $113.00).
The analyst comments "Second patient death raises concerns as use in non-ambulatory patients restricted (commercial and clinical), while enhanced immunosuppressive regimen in development... More
BMO Capital on Sarepta (SRPT) Following Earlier Downgrade: 'we believe management could potentially turn the story around'
June 16, 2025 11:07 AM EDTBMO Capital analyst Kostas Biliouris reiterated a Market Perform rating and $70.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "Management is taking all the right/necessary measures to understand the recent non-ambulatory patient deaths and prevent future ambulatory/non-ambulatory deaths. Given the significant... More
